Immunic Inc (NASDAQ:IMUX) announced that it has priced an oversubscribed private placement expected to generate up to $400 million in gross proceeds as the biotechnology company works to transition ...

Immunic raised funds to support Phase 3 clinical trials of vidofludimus calcium for MS and transition into a commercial-stage company.

Immunic (IMUX) stock surges as the company announces plans to raise up to $400M from a private placement and an upcoming leadership change. Read more here.

Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced the closing of its ...

Immunic shares jumped after the biotechnology company priced its private placement with gross proceeds of up to $400 million. The stock gained 20% to $1.051 in pre-market trading Friday. Through the ...

NEW YORK -- Immunic, Inc. (NASDAQ:IMUX) stock soared 20% Friday morning after the company announced an oversubscribed private placement that could raise up to $400 million to fund its multiple ...

A late-stage biotechnology company developing oral small-molecule therapies for neurologic and gastrointestinal diseases, led ...

US late-stage biotech Immunic, which is developing novel oral therapies for neurologic and gastrointestinal diseases, today ...

Immunic Inc IMUX is surging Friday after the late‑stage biotech announced a private placement of up to $400 million. Immunic stock is gaining positive traction. Why are IMUX shares climbing? A Look At ...

Immunic Inc. IMUX stock is surging on Friday with a robust session volume of 55.97 million compared to the average volume of ...